Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for hypertension
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. OBJECTIVE: To examine the effect of the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guidelines on the prevalence of hypertension and eligibility for initiation and intensification of treatment in nationally representative populations from the United States and China (...) . DESIGN: Observational assessment of nationally representative data. SETTING: US National Health and Nutrition Examination Survey (NHANES) for the most recent two cycles (2013-14, 2015-16) and China Health and Retirement Longitudinal Study (CHARLS) (2011-12). PARTICIPANTS: All 45-75 year old adults who would have a diagnosis of hypertension and be candidates for treatment on the basis of the ACC/AHA guidelines, compared with current guidelines. MAIN OUTCOME MEASURES: Diagnosis of hypertension and
Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib 30450475 2018 12 07 2468-0249 3 6 2018 Nov Kidney international reports Kidney Int Rep Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib. 1477-1481 10.1016/j.ekir.2018.07.005 Latcha Sheron S Renal Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Division of Pathology, Weill Cornell Medical College, New York, New York (...) Med. 2011 Oct 11;17(10):1188-9 21988993 N Engl J Med. 2009 Sep 3;361(10):947-57 19692680 J Clin Invest. 1989 Dec;84(6):1757-61 2592559 Exp Cell Res. 2009 Feb 15;315(4):602-10 18761338 Hypertension. 2008 Dec;52(6):987-93 18981331 Lancet Oncol. 2010 Jun;11(6):521-9 20493771 Cancer. 2015 Jan 15;121(2):311-9 25236375
Hypertensive Disorders of Pregnancy and Maternal Cardiovascular Disease Risk Factor Development: An Observational Cohort Study. Background: Women with a history of hypertensive disorders of pregnancy (HDP) are nearly twice as likely to develop cardiovascular disease (CVD) as those who are normotensive during pregnancy. However, the emergence of CVD risk factors after HDP is less well-understood. Objective: To identify associations between HDP and maternal CVD risk factors and chart (...) the trajectory of risk factor development after pregnancy. Design: Observational cohort study. Setting: United States. Participants: 58 671 parous NHS II (Nurses' Health Study II) participants who did not have CVD or risk factors of interest at baseline. Measurements: Women were followed for self-reported physician diagnosis of chronic hypertension and hypercholesterolemia and confirmed type 2 diabetes mellitus (T2DM) from their first birth through 2013; mean follow-up ranged from 25 to 32 years across
CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study 30271734 2018 11 14 2225-0719 6 3 2018 Sep 28 Journal of clinical and translational hepatology J Clin Transl Hepatol CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study. 241-246 10.14218/JCTH.2017.00070 Background and Aims: To evaluate the prevalence and significance of elevated cancer antigen-125 (CA-125) levels (...) that the more advanced the degree of decompensation based on MELD score, Child's Turcotte-Pugh classification and ALBI score, the higher the elevation in CA-125. Absence of ascites was associated with normal CA-125 level, with a direct correlation between high levels and worsening ascites, but there was no statistically significant correlation with esophageal varices, indicating that elevated CA-125 levels could be related to mechanical stretch of the peritoneum rather than portal hypertension itself
Usefulness of a Simple Algorithm to Identify Hypertensive Patients Who Benefit from Intensive Blood Pressure Lowering 29880288 2018 07 02 1879-1913 122 2 2018 Jul 15 The American journal of cardiology Am. J. Cardiol. Usefulness of a Simple Algorithm to Identify Hypertensive Patients Who Benefit from Intensive Blood Pressure Lowering. 248-254 S0002-9149(18)30850-6 10.1016/j.amjcard.2018.03.361 Large randomized trials have provided inconsistent evidence regarding the benefit of intensive blood (...) pressure (BP) lowering in hypertensive patients. Identifying which patients derive a higher net benefit is essential in informing clinical decision-making. We used patient-level data from 2 trials that tested intensive versus standard BP lowering, Systolic Blood Pressure Intervention Trial (SPRINT) and Action to Control Cardiovascular Risk in Diabetes (ACCORD), to assess whether stratification by cardiovascular disease (CVD) risk will identify patients with a more favorable risk-benefit profile
Effect of ibuprofen vs acetaminophen on postpartum hypertension in preeclampsia with severe features: a double-masked, randomized controlled trial 29505772 2018 05 25 1097-6868 218 6 2018 Jun American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Effect of ibuprofen vs acetaminophen on postpartum hypertension in preeclampsia with severe features: a double-masked, randomized controlled trial. 616.e1-616.e8 S0002-9378(18)30175-3 10.1016/j.ajog.2018.02.016 (...) Nonsteroidal antiinflammatory drug use has been shown to increase blood pressure in nonpregnant adults. Because of this, the American College of Obstetricians and Gynecologists suggests avoiding their use in women with postpartum hypertension; however, evidence to support this recommendation is lacking. Our goal was to test the hypothesis that nonsteroidal antiinflammatory drugs, such as ibuprofen, adversely affect postpartum blood pressure control in women with preeclampsia with severe features. At delivery, we randomized
Hypertension Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button
Hypertension Work Group: 2018 Commentary ICSI Hypertension Work Group: 2018 Commentary Background In December 2017, the American College of Cardiology/American Heart Association (ACC/AHA), and nine other professional organizations released an updated guideline on hypertension 1 . This guideline reclassified hypertension, with stage 1 hypertension now defined as systolic blood pressure (SBP) 130-139 mm Hg or diastolic blood pressure (DBP) 80-89 mm Hg and stage 2 hypertension defined as SBP = 140 (...) mm Hg or DBP = 90 mm Hg. This is a major change from the 2004 Seventh Report of the Joint National Committee (JNC 7), which defined stage 1 hypertension as SBP 140-159 mm Hg or DBP as 90-99 mm Hg and stage 2 hypertension as SBP = 160 mm Hg or DBP =100 mm Hg 2 . It is estimated that 46% of American adults will be diagnosed with hypertension by the new guideline definitions, up from 32% from the JNC 7 panel guideline 1 . Reception to the new ACC/AHA guideline has been mixed. Differing
Urinary Plasmin(ogen) as a Prognostic Factor for Hypertension 30450470 2018 12 12 2468-0249 3 6 2018 Nov Kidney international reports Kidney Int Rep Urinary Plasmin(ogen) as a Prognostic Factor for Hypertension. 1434-1442 10.1016/j.ekir.2018.06.007 Plasmin and its precursor, plasminogen, are detectable in urine from patients with glomerular disease. Urinary plasmin(ogen) levels correlate with blood pressure (BP) and may contribute to renal Na + retention by activating the epithelial Na (...) + channel (ENaC). In a longitudinal nested-cohort study, we asked whether urinary plasmin(ogen) levels predict subsequent increase in BP, incident hypertension, or mortality in subjects with type I diabetes, who often develop proteinuria. The Pittsburgh Epidemiology of Diabetes Complications (EDC) study followed up type I diabetic subjects for 25 years. Urine specimens from 70 subjects with a spectrum of baseline urinary albumin levels were examined. Outcomes included increased BP after 2 years (≥1 SD
Prospective external validation of the Predicting Out-of-OFfice Blood Pressure (PROOF-BP) strategy for triaging ambulatory monitoring in the diagnosis and management of hypertension: observational cohort study. OBJECTIVE: To prospectively validate the Predicting Out-of-OFfice Blood Pressure (PROOF-BP) algorithm to triage patients with suspected high blood pressure for ambulatory blood pressure monitoring (ABPM) in routine clinical practice. DESIGN: Prospective observational cohort study (...) . SETTING: 10 primary care practices and one hospital in the UK. PARTICIPANTS: 887 consecutive patients aged 18 years or more referred for ABPM in routine clinical practice. All underwent ABPM and had the PROOF-BP applied. MAIN OUTCOME MEASURES: The main outcome was the proportion of participants whose hypertensive status was correctly classified using the triaging strategy compared with the reference standard of daytime ABPM. Secondary outcomes were the sensitivity, specificity, and area under
Vitamin D and risk of pregnancy related hypertensive disorders: mendelian randomisation study. OBJECTIVE: To use mendelian randomisation to investigate whether 25-hydroxyvitamin D concentration has a causal effect on gestational hypertension or pre-eclampsia. DESIGN: One and two sample mendelian randomisation analyses. SETTING: Two European pregnancy cohorts (Avon Longitudinal Study of Parents and Children, and Generation R Study), and two case-control studies (subgroup nested within (...) the Norwegian Mother and Child Cohort Study, and the UK Genetics of Pre-eclampsia Study). PARTICIPANTS: 7389 women in a one sample mendelian randomisation analysis (751 with gestational hypertension and 135 with pre-eclampsia), and 3388 pre-eclampsia cases and 6059 controls in a two sample mendelian randomisation analysis. EXPOSURES: Single nucleotide polymorphisms in genes associated with vitamin D synthesis (rs10741657 and rs12785878) and metabolism (rs6013897 and rs2282679) were used as instrumental
Transient myopic shift due to ciliary body detachment as the sole ocular manifestation of hypertensive emergency â€“ A case report 30014051 2018 11 14 2451-9936 11 2018 Sep American journal of ophthalmology case reports Am J Ophthalmol Case Rep Transient myopic shift due to ciliary body detachment as the sole ocular manifestation of hypertensive emergency - A case report. 84-86 10.1016/j.ajoc.2018.06.003 Hypertensive emergency usually presents to ophthalmologists in the form of hypertensive (...) retinopathy. We present a case of hypertensive emergency that presented as bilateral transient myopic shift due to ciliary body detachment in the absence of any retinal pathology. The purpose of this paper is to showcase another ocular manifestation of hypertensive emergency. A 35 year-old female with a blood pressure of 192/114 mmHg presented to the emergency department with headache and acute onset blurry vision. Computed Tomography (CT) of the head, and lumbar puncture were within normal limits. Visual
Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with preâ€capillary pulmonary hypertension 29916558 2018 11 29 2055-5822 5 5 2018 10 ESC heart failure ESC Heart Fail Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre-capillary pulmonary hypertension. 864-875 10.1002/ehf2.12304 Pre-capillary pulmonary hypertension (PH pre-cap ) has (...) a poor prognosis, especially when caused by pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc-PAH). Whether cardiac magnetic resonance (CMR)-based quantification of atrial volumes in PH pre-cap is beneficial in risk assessment is unknown. The aims were to investigate if (i) atrial volumes using CMR are associated with death or lung transplantation in PH pre-cap , (ii) atrial volumes differ among four unmatched major PH pre-cap subgroups, and (iii) atrial volumes differ
Pulmonary Artery Size in Interstitial Lung Disease and Pulmonary Hypertension: Association with Interstitial Lung Disease Severity and Diagnostic Utility 29938208 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Pulmonary Artery Size in Interstitial Lung Disease and Pulmonary Hypertension: Association with Interstitial Lung Disease Severity and Diagnostic Utility. 53 10.3389/fcvm.2018.00053 It is postulated that ILD causes PA dilatation independent (...) of the presence of pulmonary hypertension (PH), so the use of PA size to screen for PH is not recommended. The aims of this study were to investigate the association of PA size with the presence and severity of ILD and to assess the diagnostic accuracy of PA size for detecting PH. Incident patients referred to a tertiary PH centre underwent baseline thoracic CT, MRI and right heart catheterisation (RHC). Pulmonary artery diameter was measured on CT pulmonary angiography and pulmonary arterial areas on MRI. A
Screening For Pulmonary Hypertension With Multidetector Computed Tomography Among Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation 29951486 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Screening For Pulmonary Hypertension With Multidetector Computed Tomography Among Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. 63 10.3389/fcvm.2018.00063 Aim: To assess the accuracy of multi (...) -detector computed tomography (MDCT) derived pulmonary vessel measurements in predicting pulmonary hypertension (PH) among patients with severe symptomatic aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI). Background: PH is common among patients with severe AS undergoing TAVI and is associated with adverse outcomes. MDCT is the imaging modality of choice to assess anatomical dimensions among patients selected for TAVI. Methods: One hundred and thirty-nine patients
Health insurance coverage with or without a nurse-led task shifting strategy for hypertension control: A pragmatic cluster randomized trial in Ghana 29715303 2018 05 13 1549-1676 15 5 2018 May PLoS medicine PLoS Med. Health insurance coverage with or without a nurse-led task shifting strategy for hypertension control: A pragmatic cluster randomized trial in Ghana. e1002561 10.1371/journal.pmed.1002561 Poor access to care and physician shortage are major barriers to hypertension control in sub (...) -Saharan Africa. Implementation of evidence-based systems-level strategies targeted at these barriers are lacking. We conducted a study to evaluate the comparative effectiveness of provision of health insurance coverage (HIC) alone versus a nurse-led task shifting strategy for hypertension control (TASSH) plus HIC on systolic blood pressure (SBP) reduction among patients with uncontrolled hypertension in Ghana. Using a pragmatic cluster randomized trial, 32 community health centers within Ghana's
Extracorporeal Membrane Oxygenation for Pertussis: Predictors of Outcome Including Pulmonary Hypertension and Leukodepletion PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?
Tafluprost (Saflutan) - open-angle glaucoma or ocular hypertension Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012
Selexipag (Uptravi) - for the long-term treatment of pulmonary arterial hypertension (PAH) Final Appraisal Recommendation Advice No: 0918 – May 2018 Selexipag (Uptravi ® ) 200 microgram, 400 microgram, 600 microgram, 800 microgram, 1,000 microgram, 1,200 microgram, 1,400 microgram, 1,600 microgram film-coated tablets Submission by Actelion Pharmaceuticals UK Ltd Additional note(s): • AWMSG considered selexipag (Uptravi ® ) satisfied the AWMSG criteria for a medicine developed specifically (...) for rare diseases as an ultra-orphan equivalent medicine. Recommendation of AWMSG Selexipag (Uptravi ® ) is recommended as an option for restricted use within NHS Wales. Selexipag (Uptravi ® ) is licensed for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor